Hewlett Packard
Partners HealthCare (PHS) and Hewlett Packard (HP) established a strategic relationship in the area of personalized medicine. The partnership will focus primarily on developing the appropriate infrastructure to support the various information technology needs of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG). PHS goals are to integrate genomics and genetics into routine clinical practice to more effectively and comprehensively manage patient care. PHS recognized the need for significant IT infrastructure support to successfully execute this broad initiative. To that end, PHS and HP have established a partnership, whereby both organizations will combine their collective expertise, domain knowledge, experience, and technology to specifically deliver clinical genomics solutions.Partners HealthCare (PHS) and Hewlett Packard (HP) established a strategic relationship in the area of personalized medicine. The partnership will focus primarily on developing the appropriate infrastructure to support the various information technology needs of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG). PHS goals are to integrate genomics and genetics into routine clinical practice to more effectively and comprehensively manage patient care. PHS recognized the need for significant IT infrastructure support to successfully execute this broad initiative. To that end, PHS and HP have established a partnership, whereby both organizations will combine their collective expertise, domain knowledge, experience, and technology to specifically deliver clinical genomics solutions.
Click here to see HP press release
Siemens
Partners HealthCare and Siemens Medical Solutions established a strategic alliance to jointly develop an innovative SOA (Service Oriented Architecture) infrastructure in health care IT by leveraging their respective areas of domain expertise in information technology and in healthcare to further enhance clinical services within the Soarian SOA platform.
SOA is a robust, flexible architectural design strategy that is being deployed to facilitate interoperability and integration of technology and knowledge within the framework of initiatives such as electronic health record. SOA delivers the capability to individually extend, reuse and access services.
Click here to see Siemens press release
Affymetrix
Partners HealthCare and Affymetrix established a Translational Medicine Alliance focused on developing and validating microarray based clinical diagnostic tests based on the Affymtrix GeneChip platform. The impetus for this strategic relationship was to support research and molecular diagnostic laboratories such as the Harvard Partners Center for Genetics and Genomics’ (HPCGG) Laboratory for Molecular Medicine (LMM) that share the vision of transitioning traditional testing to next generation platforms and technologies to drive efficiency and reduce costs. This multi-year, multi-agreement partnership has resulted in a number of valuable diagnostic chip-based tests for patients within and external to the Partners system.
Click here to see Affymetrix press release
Genzyme
Since September 1999, PHS and Genzyme have been engaged in a strategic alliance with the aim of furthering the patient care and drug discovery goals of the respective organizations. The alliance spans the continuum of disease areas and stages of drug discovery, and facilitates PHS-Genzyme collaboration on Basic, Clinical, and Translational research.
Millennium
In1999, Partners HealthCare and Millennium Pharmaceuticals, Inc. established a broad collaboration alliance to facilitate a pathway for Millennium-sponsored basic, translational, and clinical research. The collaboration encompasses a wide range and growing number of interactions including: 1) access to Millennium proprietary process and key technologies through facilitated sponsored research; 2) development and commercialization of inventions made during the course of research; 3) licensing of technology from Partners to Millennium; 4) sponsored research collaborations for the creation of patient data registries and the conduct of research projects to identify and characterize molecular markers in human inflammatory diseases.
MDS Proteomics
In February 2001, Partners HealthCare and MDS Proteomics (MDSP) signed a five-year agreement that would leverage both MDSP's mass-spectrometry-based protein sequencing technology and the translational research expertise of Partners scientists. The goal of this comprehensive research alliance is to understand more fully the role of protein/protein interactions, protein levels and/or protein modifications in the diagnosis, prevention and treatment of disease. The research alliance offers Partners scientists access to a core proteomics laboratory via MDSP's Boston facility. Initially, the major emphasis of this alliance will focus on research areas in oncology, infectious disease, and metabolic diseases such as diabetes, but projects in other fields will be considered as well.
Thermo Electron
In 2002, Partners HealthCare and Thermo Electron established a multi-year relationship that brings four LCQ Deca XP mass spectrometry instruments to Harvard Medical School – Partners HealthCare Center for Genetics and Genomics (HPCGG) at 65 Landsdowne Street in Cambridge, Massachusetts. The relationship with Thermo Electron marks the establishment of a functional proteomics core to support protein research endeavors across the Partners Hospitals.
Bioview
In 2002, Partners HealthCare and BioView entered into collaboration relationship to bring an innovative cell imaging technology platform to investigators at Partners. The BioView Duet System combines morphological, immuno-staining, and FISH information on the same cell and is used for research purposes and for purposes of detecting and monitoring cancer and as a diagnostic aiding tool. The scope of this relationship includes the following elements: 1) BioView and Partners investigators will collaborate on the validation of BioView system and applications through experiments that will confirm the sensitivity, reproducibility, and specificity of certain cell imaging tests, for purposes of validating the system for potential adoption and use by Partners in research and clinical laboratory settings. 2) BioView and Partners will engage in sponsored research studies to potentially develop new research and clinical applications for the BioView system.
Recombinant Data Corporation
Recombinant Data Corp., a data warehousing and clinical intelligence solutions company, is launching a suite of products developed in collaboration with Partners HealthCare to help healthcare providers make secondary use of clinical data from EHRs (electronic health records) to achieve higher quality outcomes. The product suite is the result of a three-year collaboration between Partners HealthCare and Recombinant to build solutions that address the enterprise reporting challenges of one of the nation’s leading integrated healthcare systems. At the suite’s core is the Recombinant Data Trust, which integrates and cleanses data from multiple data sources to generate a high-quality, trusted analytical health repository. Through an exclusive agreement with Partners HealthCare, Recombinant is commercially releasing Report Central and has begun implementing it in two hospital systems.